Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

The Lancet Oncology

Loncastuximab tesirine has substantial single-agent antitumour activity and produces durable responses with an acceptable safety profile, potentially offering a new therapeutic option for heavily pretreated patients with relapsed or refractory DLBCL.

  • Lonca-T had 48% ORR (24% CR) in relapsed refractory LBCL. 32% of patients had >3 lines prior therapy, 58% refractory to last line of therapy. 10% of patients went on to CAR-T with 47% response rate.